Contrasting enGene (NASDAQ:ENGN) & Immunovant (NASDAQ:IMVT)

enGene (NASDAQ:ENGN) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for enGene and Immunovant, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	9	1	3.10
Immunovant	0	0	11	0	3.00

enGene presently has a consensus target price of $30.38, indicating a potential upside of 251.16%. Immunovant has a consensus target price of $48.10, indicating a potential upside of 70.57%. Given enGene’s stronger consensus rating and higher possible upside, equities analysts clearly believe enGene is more favorable than Immunovant.

Profitability

This table compares enGene and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-66.38%	-56.00%
Immunovant	N/A	-56.40%	-52.03%

Volatility & Risk

enGene has a beta of -0.76, indicating that its stock price is 176% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Institutional and Insider Ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Comparatively, 5.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares enGene and Immunovant”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$99.92 million	N/A	N/A
Immunovant	N/A	N/A	-$259.34 million	($2.22)	-12.70

Summary

enGene beats Immunovant on 6 of the 10 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.